. Author manuscript; available in PMC: 2021 May 1.

Published in final edited form as: Liver Int. 2020 Mar 11;40(5):1111–1120. doi: 10.1111/liv.14417

Table 3:

Association of PAI-1 (1992–93, 2005–06) with prevalent NAFLD^* (2010–11)

	1^st PAI-1 Assessment 1992–93	2^nd PAI-1 Assessment 2005–06	Change in PAI-1
Unadjusted OR	2.29 (1.86, 2.81)	3.51 (2.76, 4.47)	1.87 (1.54, 2.27)
Model 1 AOR	2.06 (1.65, 2.58)	3.35 (2.62, 4.28)	1.87 (1.54, 2.28)
Model 2 AOR	1.75 (1.37, 2.23)	2.52 (1.92, 3.32)	1.66^a (1.33, 2.06)
Model 3 AOR	2.16 (1.63, 2.85)	2.71 (2.03, 3.61)	1.77^a (1.41, 2.22)

Model 1 adjusted for age, sex, race, cardia center, education, with age and education at the corresponding PAI-1 assessment

Model 2 adjusted for model 1 + risk factors (body mass index, hypertension, total cholesterol, diabetes and smoking status) at corresponding PAI-1 exam

Model 3 adjusted for model 2 + BMI at NAFLD assessment (2010–11)

Additionally adjusted for PAI-1 from 1992–93

NAFLD defined as LA≤51 HU on CT in the absence of secondary causes of steatosis

AOR reported per 1 SD higher log (PAI-1): 1^st PAI-1 assessment SD 0.84, 2^nd PAI-1 assessment SD 0.85, Change in PAI-1 SD 37.2

Abbreviations: PAI-1, plasminogen activator inhibitor 1; NAFLD, non-alcoholic fatty liver disease; OR, odds ratio; AOR, adjusted odds ratio

Diabetes defined as fasting glucose≥126 mg/dl, 2 h glucose tolerance test≥200 mg/dl, hemoglobin HbA1c≥6.5% or use of diabetic medications. Hypertension defined as antihypertensive medications use and/or systolic pressure ≥140 mmHg or diastolic pressure ≥90 mmHg.

ORs reported are for a 1 SD higher log(PAI-1) for 1^st and 2^nd assessments and 1 SD higher Change in PAI-1